12:00 AM
 | 
Apr 01, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Xeljanz tofacitinib regulatory update

Pfizer said Japan's Ministry of Health, Labor and Welfare (MHLW) approved Xeljanz tofacitinib citrate to treat rheumatoid arthritis in adult patients who have an inadequate response to existing therapies. The pharma said Xeljanz...

Read the full 145 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >